Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine.

OBJECTIVE: The objective of this article is to assess the effects of sumatriptan monotherapy, telcagepant monotherapy, and their combination on blood pressure (BP) in migraine patients during a headache-free period. METHODS: A double-blind, placebo-controlled, four-period, single-dose, randomized crossover study in 24 migraine patients was conducted. In each period, patients received a single oral dose of sumatriptan 100 mg alone, telcagepant 600 mg alone, sumatriptan 100 mg coadministered with telcagepant 600 mg, or placebo. Semi-recumbent BP was measured pre-dose and at seven post-dose time points over a period of six hours. Individual time-weighted averages in mean arterial pressure (MAP) were evaluated using a linear mixed-effects model. The pharmacokinetics of sumatriptan alone and in the presence of telcagepant were also evaluated using limited sampling times. RESULTS: The mean difference in time-weighted (0-2.5 h) MAP (90% confidence interval) was 1.2 mmHg (-0.2, 2.7) between telcagepant and placebo, 4.0 mmHg (2.5, 5.5) between sumatriptan and placebo, and 1.5 mmHg (0.0, 3.0) between telcagepant with sumatriptan vs sumatriptan alone. When coadministered with telcagepant, the AUC0-6h and C(max) of sumatriptan were increased by 23% and 24%, respectively. The small MAP increases observed after coadministration could possibly be associated with the slight elevations in sumatriptan levels. CONCLUSION: Telcagepant does not elevate mean MAP, and coadministration of telcagepant with sumatriptan results in elevations in MAP similar to those observed following administration of sumatriptan alone in migraineurs during the interictal period. When coadministered, telcagepant slightly increases the plasma levels of sumatriptan, but without an apparent clinically meaningful effect.

Mechanistic studies of a linear trisazoalkane, a new azimine, and a bicyclic triaziridine. Azoalkane homolysis into seven fragments

An aliphatic azo compound containing three azo groups (1) has been prepared by IF(5) oxidation of beta-azoamine 3. The thermolysis kinetics of this vicinal trisazoalkane were investigated above 155 degrees C, leading to a rate constant only 5.5 times faster than that of the simple model, azo-tert-butane. Because thermolysis to form seven stable products proceeds stepwise, the rate is hardly affected by the high exothermicity of the overall reaction (-93.4 kcal/mol). Oxidation of amine 3 also afforded a cyclic azimine 5 that underwent photolysis to yield a highly strained triaziridine 9 plus an unusual triazane 10, whose structures were elucidated by detailed NMR studies. On standing at ambient temperature, 9 reverted to 5 with a half-life of about an hour.

Polar bromination of cyclopropane: a DFT study

Hitherto the polar addition of bromine to cyclopropane has been considered as a two-step process. Current calculations have established the energetics for the proposed cation-anion pairs required by these mechanisms. An energetically lower pathway is proposed here in the form of a syn-cycloaddition process. Compared to the two-step process, a significantly lower activation enthalpy for this process has been found. The stereochemical consequences of the cyclic mechanism are retention-retention for the two adding moieties. This result is consistent with published experimental data on the bromination of a deuterated cyclpropane.